Fiche publication
Date publication
mai 2020
Journal
European journal of heart failure
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
Ferreira JP, Rossello X, Pocock SJ, Rossignol P, Claggett BL, Rouleau JL, Solomon SD, Pitt B, Pfeffer MA, Zannad F
Lien Pubmed
Résumé
Spironolactone up-titration may be limited by side effects that could be minimized at lower than target doses, whether lower than target doses remain efficacious is unknown. In TOPCAT, spironolactone (or placebo) were started at 15 mg/day, and increased up to a maximum of 45 mg/day. The prognostic implications related to spironolactone dose are is yet to be reported.
Mots clés
discontinuation, heart failure with preserved ejection fraction, mean dose, spironolactone, treatment effect
Référence
Eur. J. Heart Fail.. 2020 May 25;:
